Thoracic Surgery Intercostal Block Trial With Liposomal vs. Hydrochloride Bupivacaine

This randomized controlled trial evaluates the analgesic effects of liposomal bupivacaine compared to bupivacaine hydrochloride in intercostal nerve block for patients undergoing thoracoscopic lung surgery. Postoperative pain remains a significant issue in thoracic procedures, often leading to complications like pneumonia or delayed recovery. The investigators hypothesize that liposomal bupivacaine, with its extended-release properties, will provide superior pain relief beyond 24 hours compared to standard bupivacaine or no block. Participants will be randomized 1:1:1 to liposomal bupivacaine

Trial Details

NCT ID
NCT07134660
Phase
NA
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Liposomal Bupivacaine intercostal nerve block
  • Bupivacaine Hydrochloride intercostal nerve block
  • Standard Postoperative Analgesia
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Scheduled for elective unilateral thoracoscopic (VATS) lung surgery
  • Age 18 to 80 years
  • American Society of Anesthesiologists (ASA) physical status I-III

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →